JMP Securities Maintains Market Outperform on Viridian Therapeutics, Lowers Price Target to $42
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jason Butler maintains a Market Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) but lowers the price target from $44 to $42.
August 09, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Viridian Therapeutics but lowers the price target from $44 to $42.
The news is directly about Viridian Therapeutics. While the maintained Market Outperform rating is positive, the lowered price target might have a neutralizing effect on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100